General Information of Drug (ID: DMTGIP7)

Drug Name
Naphthyridine and isoquinoline derivative 1 Drug Info
Synonyms PMID26161698-Compound-51
Cross-matching ID
TTD Drug ID
DMTGIP7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [2]
Roscovitine derivative 1 DMD1G3Z N. A. N. A. Patented [1]
Tricyclic benzimidazole derivative 1 DM5SD9E N. A. N. A. Patented [1]
4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN N. A. N. A. Patented [1]
Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW N. A. N. A. Patented [1]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [1]
Flavonoid derivative 7 DM6A9UR N. A. N. A. Patented [1]
L-751250 DMOERXK Obesity 5B81 Preclinical [3]
Olomoucine DMNAFG1 N. A. N. A. Terminated [3]
aloisine A DM5U1LN Discovery agent N.A. Investigative [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [5]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [5]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [7]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [8]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [1]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [10]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [5]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [12]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [13]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [14]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [8]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [15]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [9]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [1]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 5 (CDK5) TTL4Q97 CDK5_HUMAN Inhibitor [1]

References

1 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
2 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
3 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25.
4 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
5 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
6 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
8 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
9 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
10 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
11 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
12 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
13 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
14 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
15 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
16 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.